Last reviewed 2026-04-19 · How we verify

SAR153191-C1F3 drug product

Sanofi · Phase 1 active Small molecule

SAR153191-C1F3 drug product is a Small molecule drug developed by Sanofi. It is currently in Phase 1 development. Also known as: SAR153191.

At a glance

Generic name	SAR153191-C1F3 drug product
Also known as	SAR153191
Sponsor	Sanofi
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of the Tolerability of Different SAR153191 Drug Products, That Differ With Respect to Manufacturing Processes and Formulation, at Different Concentrations and Doses in Healthy Male Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SAR153191-C1F3 drug product CI brief — competitive landscape report
SAR153191-C1F3 drug product updates RSS · CI watch RSS
Sanofi portfolio CI

Frequently asked questions about SAR153191-C1F3 drug product

What is SAR153191-C1F3 drug product?

SAR153191-C1F3 drug product is a Small molecule drug developed by Sanofi.

Who makes SAR153191-C1F3 drug product?

SAR153191-C1F3 drug product is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).

Is SAR153191-C1F3 drug product also known as anything else?

SAR153191-C1F3 drug product is also known as SAR153191.

What development phase is SAR153191-C1F3 drug product in?

SAR153191-C1F3 drug product is in Phase 1.

Manufacturer: Sanofi — full pipeline
Also known as: SAR153191
Compare: SAR153191-C1F3 drug product vs similar drugs
Pricing: SAR153191-C1F3 drug product cost, discount & access